Zasocitinib: A Promising Oral Treatment Option for Plaque Psoriasis
Takeda has released new data from Phase 3 studies of zasocitinib, a selective oral TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis. The results show that zasocitinib provided rapid and lasting skin clearance with a safety profile consistent with previous studies. The studies demonstrated that more than half of patients treated with zasocitinib achieved clear or almost clear skin at week 16, indicating its potential as an effective oral treatment option for plaque psoriasis. The positive data support zasocitinib's ability to deliver rapid and durable results with a favorable safety profile, positioning it as a promising treatment option for patients seeking an oral therapy for psoriasis.
The Phase 3 studies, Latitude PsO 3001 and 3002, showed that zasocitinib could offer clear or nearly clear skin to many individuals with moderate-to-severe plaque psoriasis. The results highlight the potential of zasocitinib to become a leading oral treatment option for psoriasis. Takeda is working diligently with regulators to advance zasocitinib as a new therapeutic option for patients in need of a safe, effective, and convenient oral treatment for plaque psoriasis. The company plans to submit a New Drug Application with the FDA and other regulatory authorities in the upcoming fiscal year.
Psoriasis is a chronic inflammatory disease caused by the body's immune system, leading to rapid skin cell multiplication. Plaque psoriasis, the most common form, is characterized by raised, red, itchy patches covered by scales. The condition can significantly impact patients' quality of life, causing itching, burning, and social isolation. Zasocitinib, a highly selective TYK2 inhibitor, has shown promising results in providing skin clearance for patients with plaque psoriasis. The Phase 3 studies have not affected Takeda's full-year forecast for the fiscal year ending March 31, 2026.
Zasocitinib is an investigational oral TYK2 inhibitor with the potential to be a leading treatment option for immune-mediated inflammatory diseases. It offers highly selective inhibition of TYK2, maintaining 24-hour inhibition of IL-23 and other immune pathways. The compound has shown greater selectivity for TYK2 compared to other JAK enzymes, potentially maximizing TYK2 inhibition without affecting JAK1, 2, and 3 signaling. Takeda is evaluating zasocitinib in head-to-head studies against deucravacitinib in plaque psoriasis and in Phase 3 trials for psoriatic arthritis. Additionally, Phase 2 studies are ongoing for Crohn's disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa.
The Phase 3 studies, conducted globally, evaluated the efficacy, safety, and tolerability of zasocitinib in adult patients with moderate-to-severe plaque psoriasis. The results demonstrated zasocitinib's potential to achieve clear or nearly clear skin in a significant proportion of patients, positioning it as a promising oral treatment option for plaque psoriasis. The studies had co-primary endpoints of sPGA 0/1 and PASI 75 response at week 16, with key secondary endpoints compared to placebo and apremilast at different time points.
TYK2 inhibitors, like zasocitinib, target immune responses fundamental to psoriasis and other inflammatory diseases. TYK2 mediates immune and inflammatory signaling pathways crucial for these conditions, making selective inhibition of TYK2 a promising therapeutic approach. Zasocitinib's highly selective allosteric inhibition of TYK2, with minimal impact on JAK1, 2, and 3, offers a potential strategy to target immune-mediated inflammation while minimizing risks associated with broader JAK family inhibition.
Takeda is committed to improving health outcomes and advancing treatment options for patients worldwide. The company focuses on developing transformative therapies in various therapeutic areas, including gastrointestinal and inflammation, rare diseases, oncology, neuroscience, and vaccines. With a diverse pipeline and a values-based approach, Takeda aims to address unmet medical needs and create a brighter future for patients and communities. For more information about Takeda and its initiatives, visit their website.